Biotech Business - March 8, 2021
ISD Immunotech enters strategic research collaboration
ISD Immunotech has entered into a strategic research collaboration with Biogen. ISD and Biogen will work together to develop ISD’s lead compound, ISD 017, which is being developed to treat severe lupus – systemic lupus erythematosus (SLE). ISD 017 is a peptide therapeutic which is an inhibitor of the stimulator of interferon genes (STING) pathway. […]
Collaboration - March 5, 2021
Oasmia enters collaboration with Karolinska Institutet
The collaboration will generate new information aiming at the development of new therapeutic APIs. The XR-17 platform technology enhances intravenous delivery of established and novel drugs in diseases including cancer, according to Oasmia. The collaboration will include a review of data and experimental methods to gain a deeper understanding of XR-17 and API formulations in […]
Collaboration - February 24, 2021
Novo Nordisk and the University of Toronto announce joint investment
The DKK 200 million investment will be used to establish the Novo Nordisk Network for Healthy Populations. The network will focus on new ways to support healthier urban populations and will draw on U of T’s expertise in public health research and education programmes to impact the global fight against diabetes and other serious chronic […]
Collaboration - February 10, 2021
NOME secures DKK 13.5 million in funding
The Nordic Mentor Network of Entrepreneurship (NOME), a Mentoring Program for Nordic life science startups, has secured new funding from the Novo Nordisk Foundation for the next three years. The new funding from the Novo Nordisk Foundation will allow NOME to expand its operations by onboarding more companies, new mentors, additional partner organizations, exploring new […]
Collaboration - February 10, 2021
Nanoform and Herantis sign Biologics Proof of Concept Agreement
Nanoform Finland and Herantis Pharma have announced that they have signed a Biologics Proof of Concept Agreement for formulation Proof of Concept projects (PoCs) aiming to enhance nasal drug delivery to the brain of Herantis’ CDNF therapies for Parkinson’s disease using Nanoform’s biological nanoparticle technology. The agreed and non-exclusive collaboration is intended to assess the […]
Collaboration - February 9, 2021
Affibody selects Biovian as a CDMO partner for ABY-062
Affibody has selected Biovian Oy as a CDMO partner for ABY-062 recombinant protein for clinical trial use. The agreement covers the technical transfer of production processes and analytics followed by non-GMP and GMP manufacturing of the ABY-062 molecule at Biovian’s facility in Turku, Finland. Analytical method validations, aseptic fill and finish of Drug Product as […]
